Methylphenidate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Methylphenidate: From ADHD to Specific Developmental Disorder (Speech Apraxia)
One-Sentence Summary
This evidence pack screened Methylphenidate (DB00422) against 10 TxGNN-predicted indications; nine are model-only signals with little or no supporting evidence (mostly Hold), but specific developmental disorder — most concretely represented by a completed Phase 2 RCT in childhood apraxia of speech — stands out as the only candidate with an actionable L2/Proceed with Guardrails rating. The prediction sits on plausible mechanistic ground given Methylphenidate’s established use in ADHD, a condition that shares neurodevelopmental biology and high comorbidity with this disorder group, but the evidence pack currently has a blocking data gap on TGA-approved Product Information, so no safety sign-off is possible yet.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ADHD, narcolepsy (general pharmacological knowledge — not captured in this evidence pack; see MOA note below) |
| Predicted New Indication | Specific developmental disorder (evidenced principally as childhood apraxia of speech) |
| TxGNN Prediction Score | 99.99% (rank 439 of full candidate list) |
| Evidence Level | L2 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as data gap DG002, High severity). Based on general pharmacological knowledge, Methylphenidate is a dopamine/norepinephrine reuptake inhibitor and central nervous system stimulant, best known for its established role in ADHD; its efficacy there is well documented, and mechanistically it may extend to related neurodevelopmental conditions.
“Specific developmental disorder” is a broad diagnostic category that overlaps substantially with ADHD — the two are frequently comorbid, and quantitative EEG (QEEG) studies cited in this pack show shared neurophysiological markers between ADHD and other specific developmental learning disorders. Methylphenidate’s effect on attention and executive function offers a biologically plausible route to benefit in this group, and this is reinforced by a completed, purpose-built Phase 2 RCT in childhood apraxia of speech (NCT05185583).
That said, the boundary between “specific developmental disorder” and ADHD itself is not sharp in the underlying data: most of the supporting trials are, on closer reading, ADHD treatment studies rather than trials independently validating this separate indication. This should be treated as a related-but-distinct signal rather than a clean, standalone repurposing case.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT05185583 | Phase 2 | Completed | 18 | Double-blind, placebo-controlled cross-over RCT of methylphenidate for speech intelligibility in children 6–12 with childhood apraxia of speech — the most directly relevant trial in the pack. |
| NCT01363544 | Phase 2/3 | Completed | 112 | Exercise + neurofeedback intervention in ADHD with a methylphenidate comparator; core neurocognitive domains overlap with developmental disorder presentations. |
| NCT05974241 | Phase 4 | Completed | 36 | Cross-over study comparing methylphenidate and aripiprazole for irritability/emotion dysregulation in children with ADHD. |
| NCT01470261 | N/A | Completed | 1398 | Large long-term surveillance (ADDUCE project) of methylphenidate’s effects on growth, neurological, psychiatric and cardiovascular systems over two years. |
| NCT04647500 | N/A | Completed | 45 | Methylphenidate’s effect on memory and executive function via dopaminergic modulation in 22q11.2 deletion syndrome, a genetic neurodevelopmental disorder with high ADHD comorbidity. |
| NCT07024303 | Early Phase 1 | Not yet recruiting | 20 | Compares medication versus behavioural treatment for challenging behaviour in children/adolescents with autism. |
| NCT05916339 | Phase 4 | Recruiting | 500 | Pragmatic SMART-design trial comparing methylphenidate and amphetamine for ADHD in children/youth with autism spectrum disorder. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8719499 | 1996 | Cohort | Clinical EEG (electroencephalography) | QEEG distinguishes children with specific developmental learning disorders from those with ADHD — the most topically direct paper in the set. |
| 20483462 | 2010 | Cohort | Psychiatry Research | EEG coherence differences between good and poor methylphenidate responders in ADHD, relevant to shared neurophysiology with developmental disorders. |
| 33012168 | 2021 | Review | Clinical EEG and Neuroscience | Review of QEEG use in childhood ADHD and learning disabilities, supporting a shared-biomarker rationale. |
| 19627998 | 2009 | Review | Neuropharmacology | Overview of ADHD neurobiology underpinning methylphenidate’s mechanism of action. |
| 40527386 | 2025 | Longitudinal MRI study | Progress in Neuro-Psychopharmacology & Biological Psychiatry | Age-dependent effects of cumulative methylphenidate exposure on brain structure and symptom improvement in youth with ADHD. |
| 41128391 | 2026 | Dual-tracer PET study | Psychiatry and Clinical Neurosciences | Longitudinal PET study of extended-release methylphenidate’s effects on dopamine and norepinephrine transporters in adults with ADHD. |
| 22923783 | 2015 | Review | Journal of Attention Disorders | Review of methylphenidate’s cellular/molecular mechanisms and developmental consequences across juvenile and adult brains. |
| 36899043 | 2023 | Qualitative study | Scientific Reports | Adolescent and psychiatrist perspectives on methylphenidate use in ADHD. |
| 25989180 | 2015 | Genetic/pharmacogenetic study | Genes, Brain, and Behavior | LPHN3 gene variants linked to ADHD susceptibility and methylphenidate treatment response. |
| 36688969 | 2024 | Study | European Child & Adolescent Psychiatry | Effects of methylphenidate and physiotherapy on graphomotor (handwriting) movements in children with ADHD — relevant to motor-developmental overlap. |
Australia Market Information
No ARTG entries are recorded for Methylphenidate in this evidence pack (market status: Not Marketed, 0 licences on file). No product name, dosage form, or approved indication text is available to report.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for structured safety information — the standard warnings, contraindications, and drug interaction fields in this evidence pack are all data gaps (DG001, Blocking severity: this alone blocks progression to the S1 safety review stage).
One safety-relevant literature signal did surface incidentally, from a related TxGNN candidate in this same pack rather than the structured safety fields: case reports describe methylphenidate/stimulant treatment triggering or worsening trichotillomania in paediatric patients, particularly those with comorbid autism/ADHD (PMID 21586916, 28492426, 28394174, 31984712). This is a signal worth flagging to prescribers even though it falls outside the formal DDI/warnings dataset.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Among the 10 TxGNN-predicted indications in this pack, “specific developmental disorder” is the only one supported by a completed, indication-specific Phase 2 RCT (childhood apraxia of speech) plus a plausible shared-biomarker rationale (QEEG overlap with ADHD). However, the indication boundary versus ADHD itself is not clean, and the missing TGA Product Information data (DG001, Blocking) means safety sign-off cannot yet proceed.
To proceed, the following is needed:
- TGA-approved Product Information (warnings, contraindications, DDI) to clear the blocked S1 safety review
- Confirmed mechanism of action data from DrugBank (currently a data gap)
- Clarification of how “specific developmental disorder” is being defined/coded relative to ADHD, to confirm this is a genuinely distinct indication rather than an ADHD-adjacent artefact
- Assessment of the trichotillomania adverse-signal literature as part of the safety profile
- Confirmation of current ARTG/product registration status in Australia, since this pack shows 0 licences on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.